{Reference Type}: Journal Article
{Title}: Efficacy of sucrose and povidone-iodine mixtures in peritoneal dialysis catheter exit-site care.
{Author}: Nakayama T;Morimoto K;Uchiyama K;Washida N;Kusahana E;Hama EY;Mitsuno R;Tonomura S;Yoshimoto N;Hishikawa A;Hagiwara A;Azegami T;Yoshino J;Monkawa T;Yoshida T;Yamaguchi S;Hayashi K;
{Journal}: BMC Nephrol
{Volume}: 25
{Issue}: 1
{Year}: 2024 May 2
{Factor}: 2.585
{DOI}: 10.1186/s12882-024-03591-1
{Abstract}: <B>BACKGROUND: </B>Exit-site infection (ESI) is a common recurring complication in patients undergoing peritoneal dialysis (PD). Sucrose and povidone-iodine (SPI) mixtures, antimicrobial ointments that promote wound healing, have been used for the treatment of ulcers and burns, but their efficacy in exit-site care is still unclear.<BR><B>METHODS: </B>This single-center retrospective observational study included patients who underwent PD between May 2010 and June 2022 and presented with episodes of ESI. Patients were divided into SPI and non-SPI groups and followed up from initial ESI onset until PD cessation, death, transfer to another facility, or June 2023.<BR><B>RESULTS: </B>Among the 82 patients (mean age 62, [54-72] years), 23 were treated with SPI. The median follow-up duration was 39 months (range, 14-64), with an overall ESI incidence of 0.70 episodes per patient-year. Additionally, 43.1% of second and 25.6% of third ESI were caused by the same pathogen as the first. The log-rank test demonstrated significantly better second and third ESI-free survival in the SPI group than that in the non-SPI group (p < 0.01 and p < 0.01, respectively). In a Cox regression analysis, adjusting for potential confounders, SPI use was a significant predictor of decreased second and third ESI episodes (hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.10-0.52 and HR, 0.22; 95%CI, 0.07-0.73, respectively).<BR><B>CONCLUSIONS: </B>Our results showed that the use of SPI may be a promising option for preventing the incidence of ESI in patients with PD.<BR><B>BACKGROUND: </B>This study was approved by the Keio University School of Medicine Ethics Committee (approval number 20231078) on August 28, 2023. Retrospectively registered.